Designing Longevity
Skip to main content
Emerging ResearchPeptide

Epithalon

Epitalon / AEDG

Pineal Tetrapeptide

Last updated: August 2026
Share:

Evidence Level: Emerging Research

Very new, early-stage research, high uncertainty

Regulatory Status: Not approved anywhere. Placed in FDA 503A Category 2 in 2023. On July 24, 2026 an FDA advisory committee voted to recommend adding it to the permitted 503A list; that vote is advisory and non-binding.

Epithalon is a four-amino-acid peptide (alanine, glutamate, aspartate, glycine) developed in Russia as a simplified version of a bovine pineal gland extract. It is claimed to activate and lengthen . Cell studies support the telomerase effect. No controlled human trial has ever measured telomere length before and after taking it.

How It Works

The pitch for epithalon runs straight at one of the most compelling ideas in aging biology, which is exactly why it is so heavily marketed.

and why anyone cares. are protective caps on the ends of your chromosomes. Every time a cell divides they get slightly shorter, and when they get short enough the cell stops dividing and becomes senescent. Telomere shortening is one of the recognized hallmarks of aging. is the enzyme that rebuilds them, and most adult cells switch it off.

What epithalon is supposed to do. Activate in normal cells, restoring their ability to maintain length, and by extension extend how many times they can divide before senescing.

Where it came from. Vladimir Khavinson's laboratory at the St. Petersburg Institute of Bioregulation and Gerontology developed it as a synthetic simplification of Epithalamin, an extract of bovine pineal gland. That origin matters for reading the literature: for roughly two decades, essentially all the evidence came from one research group in one city.

The 2025 replication, and its sting. In 2025 researchers at Brunel University London published an independent study in Biogerontology. This was the first substantial Western replication attempt, and it did confirm the core finding: epitalon increased length in human cell lines through upregulation.

It also found something the marketing does not mention. The paper's own title says it: length increased "through upregulation or ALT activity." ALT stands for alternative lengthening of telomeres, and it is a mechanism that cancer cells use to become immortal when telomerase is unavailable to them. The study examined normal breast epithelial cells, fibroblasts, and breast cancer cell lines, and found epitalon engaging telomere-lengthening machinery in the cancer lines too.

That is not proof that epithalon causes cancer. It is a genuine mechanistic red flag in a compound people take for years for prevention, and it is the single most important thing published about epithalon in twenty years.

What is still missing. No completed human clinical trial has measured length before and after epithalon administration under controlled conditions. The Russian human studies that circulate are largely uncontrolled, are published in Russian-language journals, and include mortality claims that have never been independently verified. A cell-culture finding, even a replicated one, does not tell you what happens in a person.

Evidence by Outcome

Each claim below is rated using a GRADE-aligned five-tier system. Same molecule, different outcomes, different evidence.

Evidence at a glance

How we grade

Want to see how this compares to every other peptide? Browse the full evidence matrix, where every graded claim is grouped by outcome and sorted by certainty.

Longevity biomarkersPreclinical certainty

Activates telomerase and increases telomere length in human cell lines.

Population: Human cell lines in culture. No human population has been studied.

Why this rating

This is the best-supported epithalon claim and it has now been independently replicated outside the originating laboratory, which is genuinely meaningful. It remains preclinical because it is a cell-culture finding. Cells in a dish are not a person: they lack the immune surveillance, tissue architecture, and pharmacokinetics that determine what actually happens in a body.

Supporting studies

Reviewed 2026-08-24· Designing Longevity EditorialHow we grade
Longevity biomarkersPreclinical certainty

Lengthens telomeres in people who take it.

Population: No controlled human study has measured this.

Why this rating

We could not identify any completed, peer-reviewed, controlled human trial that measured telomere length before and after epithalon administration. This is the central claim made for the compound and it is entirely unmeasured in humans. The gap between "activates telomerase in a dish" and "lengthens your telomeres" is the whole question, and nobody has closed it.

Supporting studies

Reviewed 2026-08-24· Designing Longevity EditorialHow we grade
Longevity biomarkersVery Low certainty

Extends human lifespan or reduces mortality.

Population: Elderly Russian cohorts in uncontrolled studies.

Why this rating

Russian studies reporting reduced mortality in elderly cohorts given Epithalamin or epithalon are uncontrolled, come from the group that developed the compound, and have not been independently verified. Uncontrolled survival data in elderly populations is among the least reliable evidence in medicine, because who receives an intervention and who survives are both driven by baseline health.

GRADE downgrade factors applied

  • Risk of bias: Methodological flaws in the studies (e.g. lack of blinding, allocation concealment, high attrition).
  • Publication bias: Suspicion that negative or null results were not published, inflating apparent effect.
  • Imprecision: Wide confidence intervals or small sample size, the estimate could be substantially different.

Supporting studies

  • Russian cohort studies of Epithalamin and epithalon in elderly subjectsObservational Study

    Reported reduced mortality in treated elderly cohorts, without randomization, blinding, or independent verification.

Reviewed 2026-08-24· Designing Longevity EditorialHow we grade

Potential Benefits

  • A genuinely interesting mechanism aimed at one of the recognized hallmarks of aging
  • The -activation finding was independently replicated by a Western lab in 2025, which is more than most longevity peptides can say
  • Cell culture work shows extended replicative lifespan in human fibroblasts
  • Long history of use in Russia with no widely reported acute safety problems
  • Short peptide, so it is chemically simple and stable
  • An FDA advisory committee voted in July 2026 to recommend it for the permitted compounding list

Risks & Considerations

  • The 2025 independent study found epitalon activating ALT, a -lengthening mechanism cancer cells use, in tumor cell lines
  • No controlled human trial has ever measured length before and after administration
  • The Russian human studies, including the survival claims, are uncontrolled and have not been independently verified
  • Activating is theoretically double-edged: the same capability that lets normal cells keep dividing is one cancer needs to become immortal
  • Almost all supporting data comes from a single research group over two decades
  • Not approved anywhere, so supply is unregulated with unverified identity and purity
  • Marketed for cancer prevention and life extension, claims with no controlled human evidence at all

Dosing Information

There is no established human dose from controlled trials. What circulates comes from Russian clinical convention and community practice.

  • •Common community protocol: 5 to 10mg per day subcutaneously for 10 to 20 days, repeated once or twice per year
  • •The intermittent course structure is Russian clinical convention rather than a trial-derived schedule
  • •Some protocols use intranasal administration, with no comparative human data
  • •No dose-response relationship has been established in humans
  • •We are not endorsing a protocol for a compound with an unresolved cancer-mechanism question

Need to mix this from a vial?

Use our reconstitution calculator to get the exact insulin syringe units to draw.

Practical Tips

  • 1Read the 2025 Brunel paper title before you buy. The ALT finding is in the title, and it is the part vendors omit
  • 2If you have a personal or family history of cancer, this is a compound to discuss with an oncologist first, not a wellness clinic
  • 3 length testing is available commercially but is noisy and poorly standardized, so do not expect it to tell you much
  • 4Be skeptical of the Russian mortality studies. Uncontrolled survival data in elderly cohorts is among the least reliable evidence there is
  • 5If longevity is your goal, the interventions with human outcome data (exercise, sleep, blood pressure control, not smoking) still outperform everything in this category

Key Research

Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity

Biogerontology, 2025

An independent UK group confirmed dose-dependent telomere lengthening in human cell lines via telomerase upregulation, and also found telomere lengthening through the ALT pathway, a mechanism associated with cancer cell immortalization, in cancer cell lines.

View Study

Epithalon and replicative lifespan in human fibroblasts

Khavinson laboratory, St. Petersburg, 2004

Treated human fibroblasts completed roughly 44 population doublings versus 34 in untreated controls, with reported telomerase activation.

FDA Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026

FDA advisory committee proceedings, 2026

The committee voted to recommend epitalon for the 503A bulk drug substances list, with the proposed use under discussion being insomnia. The vote was reported as narrow, is advisory, and does not change its legal status without FDA rulemaking.

View Study

Want to learn more?

Explore related content and talk to a healthcare provider.

Browse All TreatmentsFind Your Goal

Always consult a healthcare provider before starting any treatment.This treatment has very early human evidence.

Frequently Asked Questions

Does epithalon lengthen telomeres in humans?

Nobody has measured it. No completed, peer-reviewed, controlled human trial has assessed length before and after epithalon administration. The evidence that exists is from cell culture, where the effect has now been independently replicated. That is a meaningful result about cells in a dish and it does not tell you what happens in a human body.

What did the 2025 study find?

Researchers at Brunel University London published the first substantial independent Western replication in the journal Biogerontology. They confirmed that epitalon increases length in human cell lines through upregulation. They also found it lengthening telomeres through ALT, alternative lengthening of telomeres, which is a mechanism cancer cells use to become immortal, in cancer cell lines. Both findings are in the paper title.

Is epithalon safe? Could it cause cancer?

The honest answer is that the cancer question is open and the 2025 study made it more pressing, not less. Activating is theoretically double-edged: the ability to keep dividing indefinitely is exactly what a cancer cell needs. Finding epitalon engaging ALT in cancer cell lines is a real mechanistic flag. No human study has assessed cancer risk. If you have a personal or family cancer history, this is an oncologist conversation.

Is epithalon legal?

It is not approved anywhere. The FDA placed it in of the bulk substances list in 2023. On July 24, 2026 an FDA advisory committee voted to recommend adding epitalon to the permitted 503A list, with insomnia among the discussed uses. That vote was narrow, is advisory, and does not change its legal status without FDA rulemaking that typically takes 12 to 24 months.

Why is most epithalon research from one lab?

Because epithalon was developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology, and for roughly twenty years essentially all published work came from that group. Independent replication is how science separates real effects from lab-specific artifacts, and until 2025 it had barely happened. That is why the Brunel study matters so much, in both directions.

How is epithalon different from NMN or rapamycin for longevity?

They target different hallmarks of aging and sit at very different evidence levels. Rapamycin has extended lifespan in mice repeatedly and has ongoing human trials. NMN has human trials showing it raises NAD+, though not that it improves health outcomes. Epithalon has cell-culture evidence for its mechanism and no controlled human data of any kind. Of the three, it has the thinnest human evidence base.

What is the difference between epithalon and epitalon?

Nothing. They are two transliterations of the same Russian name for the same four-amino-acid peptide, sometimes also written as AEDG after its amino acid sequence. "Epitalon" appears more often in translated Russian publications and "epithalon" more often in commercial listings.

New to Peptides?

Learn the basics of peptide therapy, how to inject safely, and what to look for in quality sources.

What Are Peptides? Peptide Safety Guide

Related Goals

The Slow Aging Guide

Related Peptides

MOTS-cMitochondrial-Derived Peptide
HumaninMitochondrial-Derived Peptide

Disclaimer: This information is for educational purposes only and is not medical advice. Many peptides discussed are not FDA-approved for human use. Always consult with a qualified healthcare provider before starting any treatment. Evidence levels and regulatory status can change, this content was last updated August 2026.

Found this helpful? Share it or save it for later.

Share: